Saturday, October 18 2008
The FDA announced that the psoriasis drug Raptiva is getting a "black box" warning, due to the risk of life-threatening infections including a Progressive multifocal leukoencephalopathy (PML), rare brain infection and viral meningitis. Raptiva is a psoriasis medication given by injection once a week to treat moderate to severe plaque psoriasis in adults.Raptiva works by suppressing the immune system to reduce psoriasis flare-ups, but suppressing the immune system can raise the risk of serious infections and malignancies. [Oct 16, 2008] No FDA Raptiva Recall has been announced. See more information about FDA Raptiva Brain Infection & Viral Meningitis Warnings |